Analysis and comparison of statin prescription patterns and outcomes according to clinical department

H-S Kim1,2, H Kim3, H Lee4

  • 1Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Insights

This study found that statin prescription patterns vary by department, with cardiology and endocrinology most frequently prescribing them. Achieving low-density lipoprotein cholesterol (LDL-C) targets requires higher potency statins and greater physician awareness of patient risk factors.

Area of Science:

  • Cardiology
  • Endocrinology
  • Clinical Pharmacy

Background:

  • Clinical practice guidelines for managing dyslipidemia, particularly low-density lipoprotein cholesterol (LDL-C) targets, exist but may not align with real-world prescribing habits.
  • Disparities in statin prescription patterns and achievement of LDL-C goals across different medical departments warrant investigation.

Purpose of the Study:

  • To evaluate department-specific differences in statin prescription patterns.
  • To assess the achievement rates of LDL-C targets based on these departmental prescribing habits.
  • To identify factors influencing LDL-C target attainment.

Main Methods:

  • Retrospective analysis of data from 31,718 patients prescribed statins between January 2008 and June 2013.
  • Classification of patients into high-risk (LDL-C < 100 mg/dL) and moderate-risk (LDL-C < 130 mg/dL) groups based on NCEP-ATP III guidelines.
  • Analysis of statin potency and departmental prescription data.

Main Results:

  • Cardiology (32.0%) and endocrinology (26.6%) were the leading departments for statin prescriptions.
  • High-risk patients in cardiology, endocrinology, and cardiac surgery achieved LDL-C targets (>70%) more frequently than other departments.
  • Higher prescription rates of high- and intermediate-potency statins correlated positively with achieving LDL-C targets (<100 mg/dL).

Conclusions:

  • Significant variations exist in statin prescribing practices and LDL-C goal achievement across medical departments.
  • Under-treatment of hyperlipidemia may occur in certain departments, highlighting a gap between guidelines and practice.
  • Increased physician awareness of individual patient risk factors and active consideration of statin potency are crucial for improving LDL-C target attainment.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
393
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
578
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
321
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
457